TSC Seizures Clinical Trial Opens in Montreal & Vancouver
**This study is ongoing, but not recruiting participants.
The EXIST3 clinical trial will soon be recruiting patients from across the country at two Canadian centres, one at the Montreal TSC Clinic, and one at the Vancouver TSC Clinic.
EXIST3 is a three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex who have refractory partial-onset seizures.
The primary objective is to compare the reduction in frequency of partial-onset seizures on each of trough ranges of everolimus (3-7 ng/mL and 9-15 ng/mL) versus placebo in patients with TSC.
To be eligible for the trial, patients must:
- Be between ages 2-65
- Have a clinically definite diagnosis of TSC
- Have a diagnosis of partial-onset epilepsy
For more information on eligibility and other details, see: the clinical trials website. Stay tuned to this page for updates on these clinical trials.
Clinical Trials Outside of Canada
Early Biomarkers of Autism in Infants with Tuberous Sclerosis Complex (TACERN)
Visit the NINDS Clinical Trials study page or the Tuberous Sclerosis Complex Autism Center of Excellence Network (TACERN) webpage for more information.